Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Ten new option listings and two option delistings on January 23rd » 08:30
01/23/20
01/23
08:30
01/23/20
08:30
AKRO

Akero Therapeutics

$23.34 /

+0.46 (+2.01%)

, AQST

Aquestive Therapeutics

$3.90 /

-0.2 (-4.88%)

, CYCN

Cyclerion Therapeutics

$3.75 /

+0.23 (+6.53%)

, ITRN

Ituran

$25.31 /

-0.51 (-1.98%)

, OBSV

ObsEva

$4.39 /

-0.09 (-2.01%)

, PHAS

PhaseBio

$5.43 /

-0.2 (-3.55%)

, PHAT

Phathom Pharmaceuticals

$38.10 /

+1.29 (+3.50%)

, STOK

Stoke Therapeutics

$23.87 /

+0.52 (+2.23%)

, XP

XP Inc.

$42.45 /

+1.845 (+4.54%)

, MDR

McDermott

$0.70 /

+ (+0.00%)

, TOO

Teekay Offshore Partners

$1.54 /

-0.005 (-0.32%)

New option listings for…

New option listings for January 23rd include Akero Therapeutics Inc (AKRO), Aquestive Therapeutics Inc (AQST), Cyclerion Therapeutics Inc (CYCN), Ituran (ITRN), McDermott International Inc (MDRIQ), ObsEva (OBSV), PhaseBio Pharmaceuticals Inc (PHAS), Phathom Pharmaceuticals Inc (PHAT), Stoke Therapeutics Inc (STOK), and XP Inc (Class A Stock) (XP). Option delistings effective January 23rd include McDermott International Inc (MDR) and Teekay Offshore Partners LP (Units) (TOO).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
JPMorgan to hold a conference » 09:58
01/15/20
01/15
09:58
01/15/20
09:58
ABBV

AbbVie

$88.50 /

+0.265 (+0.30%)

, AKRO

Akero Therapeutics

$19.90 /

+0.07 (+0.35%)

, GKOS

Glaukos

$59.98 /

+0.6 (+1.01%)

, MORF

Morphic Holding

$18.99 /

+ (+0.00%)

, RCM

R1 RCM

$13.54 /

+0.01 (+0.07%)

, TWST

Twist Bioscience

$21.82 /

+0.32 (+1.49%)

, XRAY

Dentsply Sirona

$59.02 /

+0.27 (+0.46%)

, QDEL

Quidel

$81.18 /

+0.88 (+1.10%)

, CYCN

Cyclerion Therapeutics

$3.58 /

-0.095 (-2.59%)

, HQY

HealthEquity

$72.39 /

+0.29 (+0.40%)

, PCRX

Pacira

$43.51 /

+0.27 (+0.62%)

, AKBA

Akebia

$6.96 /

+0.06 (+0.87%)

, ALKS

Alkermes

$19.50 /

+0.06 (+0.31%)

, ITCI

Intra-Cellular

$26.97 /

+0.17 (+0.63%)

, AVNS

Avanos

$33.32 /

+0.33 (+1.00%)

, BCRX

BioCryst

$2.81 /

+0.04 (+1.44%)

, NVST

Envista

$31.84 /

+0.345 (+1.10%)

, ANAB

AnaptysBio

$15.31 /

+0.3 (+2.00%)

, TECH

Bio-Techne

$218.01 /

+ (+0.00%)

, TMDX

TransMedics

$19.44 /

+ (+0.00%)

, OBSV

ObsEva

$3.68 /

-0.03 (-0.81%)

, IART

Integra LifeSciences

$58.27 /

-0.23 (-0.39%)

, CRNX

Crinetics

$25.26 /

+ (+0.00%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16 with webcasted company presentations to begin on January 15 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ObsEva, Yuyuan announce sublicense agreement to develop, commercialize nolasiban » 05:10
01/13/20
01/13
05:10
01/13/20
05:10
OBSV

ObsEva

$3.56 /

-0.05 (-1.39%)

ObsEva and Yuyuan…

ObsEva and Yuyuan BioScience Technology announced that they have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization, or IVF, in the People's Republic of China, or PRC. Nolasiban is a novel, oral oxytocin receptor antagonist, for which two Phase 3 studies have been completed in Europe. Under the terms of the agreement, Yuyuan has the exclusive rights to develop and commercialize nolasiban in the PRC. They will fund all development and registration activities in the PRC starting with the commitment to fund and conduct a Phase 1 study and a Phase 2 Proof-of-Concept study in China. Both companies plan to collaborate on the subsequent global development of nolasiban, but Obseva will retain worldwide rights to the product outside of the PRC. In addition, both companies will seek to expand their collaboration in China on other projects. Financial terms of the deal are not being disclosed.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
ObsEva price target raised to $40 from $36 at H.C. Wainwright » 08:11
12/19/19
12/19
08:11
12/19/19
08:11
OBSV

ObsEva

$2.97 /

+0.1 (+3.48%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva to $40 from $36 saying the company reported positive top-line data from one of two pivotal Phase 3 trials of linzagolix, its lead gonadotropin-releasing hormone receptor antagonist candidate for treatment of endometriosis and uterine fibroids. The analyst continues to expect linzagolix to demonstrate a "best-in-class" product profile overall within the GnRH receptor antagonist class. He reiterates a Buy rating on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kezar Life Sciences appoints Elizabeth Garner to board of directors » 07:13
12/19/19
12/19
07:13
12/19/19
07:13
KZR

Kezar Life Sciences

$3.04 /

+0.175 (+6.11%)

, OBSV

ObsEva

$2.97 /

+0.1 (+3.48%)

Kezar Life Sciences (KZR)…

Kezar Life Sciences (KZR) announced the appointment of Elizabeth Garner, MD, MPH to its Board of Directors. Dr. Garner is currently the CMO of ObsEva (OBSV).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
ObsEva to host conference call » 07:25
12/09/19
12/09
07:25
12/09/19
07:25
OBSV

ObsEva

$4.60 /

+0.29 (+6.73%)

Conference call to…

Conference call to discuss PRIMROSE 2 trial results will be held on December 9 at 8 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ObsEva says PRIMROSE 2 Phase 3 trial met primary, secondary efficacy endpoints » 05:10
12/09/19
12/09
05:10
12/09/19
05:10
OBSV

ObsEva

$4.60 /

+0.29 (+6.73%)

ObsEva reported positive…

ObsEva reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding, or HMB, due to uterine fibroids. The PRIMROSE 2 trial enrolled 535 women with HMB due to uterine fibroids. The trial was conducted in Europe and the U.S. and evaluated the efficacy and safety of once daily oral linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy, or ABT. The primary efficacy endpoint was the reduction in HMB. Responders were defined as patients with menstrual blood loss volume of less than or equal to 80 mL and greater than or equal to 50% reduction from baseline in menstrual blood loss volume at 24 weeks, measured using the alkaline hematin method. Bone mineral density, or BMD, was assessed centrally using Dual Energy X-ray Absorptiometry, or DEXA, scan at baseline and 24 weeks. The responder rate was 93.9% for women receiving 200 mg with ABT and 56.7% for women receiving 100 mg without ABT, compared to 29.4% in the placebo group. Both doses achieved significant rates of amenorrhea, reduction in pain, and improvement in quality of life. Additionally, significant improvement in hemoglobin levels, a reduction in number of days of bleeding and reduction in uterine volume were observed. Furthermore, a significant reduction in fibroid volume was also observed for the 200 mg dose with ABT. The overall safety profile was in line with expectations and confirmed that linzagolix was well-tolerated. The most frequently observed adverse events, occurring in greater than 5% of patients, were headache, hot flushes, and anemia. Mean percentage change from baseline in BMD was consistent with previous clinical data.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
ObsEva price target lowered to $36 from $44 at H.C. Wainwright » 07:07
12/02/19
12/02
07:07
12/02/19
07:07
OBSV

ObsEva

$4.54 /

+0.34 (+8.10%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for ObsEva to $36 from $44 after the company last month reported that the Implant 4 trial of nolasiban had failed to meet its primary endpoint. The analyst, however, feels that ObsEva shares remain undervalued solely based on the prospects of linzagolix. He reiterates a Buy rating on the name.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
ObsEva downgraded to Neutral from Outperform at Credit Suisse » 06:40
11/08/19
11/08
06:40
11/08/19
06:40
OBSV

ObsEva

$2.83 /

-5.12 (-64.40%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster downgraded ObsEva to Neutral from Outperform with a price target of $4, down from $16. The failure of nolasiban removes a major potential upside driver from the stock and reduces the company's financing flexibility, Auster tells investors in a research note. ObsEva will now need to secure additional financing to fund operations through linzagolix endometriosis Phase 3 results and subsequent commercial launch, the analyst adds. When combined with an "increasingly challenging" commercial proposition for linzagolix, he sees a "difficult development path ahead" for the company.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ObsEva says IMPLANT 4 study did not meet primary endpoint » 05:43
11/07/19
11/07
05:43
11/07/19
05:43
OBSV

ObsEva

$7.95 /

+0.18 (+2.32%)

ObsEva SA announced that…

ObsEva SA announced that the Phase 3 clinical trial results from its European confirmatory study of nolasiban, or IMPLANT 4, in women undergoing embryo transfer, or ET, following in-vitro fertilization, or IVF, did not meet the primary endpoint of an increase in ongoing pregnancy rate at 10 weeks. Nolasiban was well tolerated. All subjects will continue to be followed up to delivery and infant development will be assessed up to 6 months.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.